Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug563 | COPAN swabbing and blood sample collection Wiki | 1.00 |
drug3132 | Standard care Wiki | 0.33 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
40 COVID-19 survivors that have been discharged from the hospital will be included in this investigator-blinded randomised study with a 12-week exercise intervention. Patients will be 1:1 block-randomised by sex to either a supervised high intensity interval-based exercise group or standard care (control group).
Description: measured by MRI scan
Measure: Change in left ventricular mass Time: Through study completion, an average of 12 monthsDescription: measured by MRI scan
Measure: Change in right ventricular volume Time: Through study completion, an average of 12 monthsDescription: Structural cardiac parameter: measured by MRI scan and echocardiography
Measure: Stroke volume Time: Through study completion, an average of 12 monthsDescription: Structural cardiac parameter: measured by MRI scan and echocardiography
Measure: end-diastolic volume Time: Through study completion, an average of 12 monthsDescription: Structural cardiac parameter: measured by MRI scan and echocardiography
Measure: IVS thickness (intact ventricular septum) Time: Through study completion, an average of 12 monthsDescription: Structural cardiac parameter: measured by MRI scan and echocardiography
Measure: LVID (left ventricular internal dimensions) Time: Through study completion, an average of 12 monthsDescription: Structural cardiac parameter: measured by MRI scan and echocardiography
Measure: PWT (posterior wall thickness) Time: Through study completion, an average of 12 monthsDescription: Structural cardiac parameter: measured by MRI scan and echocardiography
Measure: LAVI (left atrial volume index) Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: LVEF Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: Global longitudinal strain Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: E/A ratio Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: E´ Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: RV volumes Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: RVEF Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: TAPSE Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: Change in maximal tricuspid regurgitation velocity and pressure gradient Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: RV s´ Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: Peak E velocity Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: Peak A velocity Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: Septal e´ Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: Lateral e´ Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: E/e´ septal Time: Through study completion, an average of 12 monthsDescription: Functional cardiac parameters: measured by MRI scan and echocardiography
Measure: E/e´ lateral Time: Through study completion, an average of 12 monthsDescription: measured with gadolinium and MRI scan
Measure: Cardiac inflammation Time: Through study completion, an average of 12 monthsDescription: measured with gadolinium and MRI scan
Measure: Vascular dysfunction Time: Through study completion, an average of 12 monthsDescription: measured with gadolinium and MRI scan
Measure: Extracellular volume Time: Through study completion, an average of 12 monthsDescription: measured with gadolinium and MRI scan
Measure: Diffuse fibrotic changes Time: Through study completion, an average of 12 monthsDescription: changes
Measure: Blood and plasma volume Time: Through study completion, an average of 12 monthsDescription: easuring Lean mass, Fat mass and BMD
Measure: Body composition analysis measured with DXA Time: Through study completion, an average of 12 monthsDescription: Measured with an incremental VO2 protocol on exercise bike
Measure: Cardiorespiratory fitness Time: Through study completion, an average of 12 monthsDescription: Pulmonary function testing
Measure: Dynamic spirometri Time: Through study completion, an average of 12 monthsDescription: Pulmonary function testing
Measure: Whole body plethymography Time: Through study completion, an average of 12 monthsDescription: Pulmonary function testing
Measure: Diffusion capacity Time: Through study completion, an average of 12 monthsDescription: 75g of glucose taken while fasting
Measure: Oral glucose tolerance test Time: 2 hours at baseline and same after interventionDescription: Three days of continuous glucose monitoring (CGM) is performed using enzyme-coated electrodes (iPro MMT- 7745WW; Medtronic, Northridge, CA, USA) placed subcutaneously in the abdominal wall. For calibration of the CGM system, finger-prick blood glucose measurements are performed by the participant four times daily.
Measure: Continuous glucose monitoring Time: 3 days at baseline and same after interventionDescription: Free-living physical activity is measured using axial accelerometer-based physical activity monitors (AX3; Axivity, Newcastle upon Tyne, UK) for a 4-day period
Measure: Axial accelerometer-based physical activity monitors Time: 4 days at baseline and same after interventionDescription: Including high-sensitivity C-reactive protein, tumour necrosis factor-α, IL-1RA, interferon-γ and interleukins (IL-6, IL-10 and others) Following an overnight fast (10 hours), blood samples, are collected and processed by a trained laboratory technician and analysed according to standard procedures. Plasma is stored at - 80 °C prior to analysis.
Measure: Blood samples analysed for markers related to low grade inflammation Time: Through study completion, an average of 12 monthsDescription: Including total troponins, D-dimer, creatinine kinase, total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, glycated haemoglobin, fasting insulin, fasting plasma glucose, pro-brain natriuretic peptide, haematology, electrolytes and liver and renal status. Following an overnight fast (10 hours), blood samples, are collected and processed by a trained laboratory technician and analysed according to standard procedures. Plasma is stored at - 80 °C prior to analysis.
Measure: Blood samples analysed for markers related to cardiometabolic biomarkers. Time: Through study completion, an average of 12 monthsDescription: Questionnaires on quality of life will be filled in on baseline and after the intervention
Measure: SF-36, King´s Brief Interstitial Lung Disease Questionnaire, Post-COVID-19 Functional Status Time: Through study completion, an average of 12 monthsDescription: Questionnaires on quality of life will be filled in on baseline and after the intervention
Measure: King´s Brief Interstitial Lung Disease Questionnaire Time: Through study completion, an average of 12 monthsDescription: Questionnaires on quality of life will be filled in on baseline and after the intervention
Measure: Post-COVID-19 Functional Status Time: Through study completion, an average of 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports